Investing Ideas
/
Australian Pharmaceuticals & Biotech Potentially Undervalued Companies

Australian Pharmaceuticals & Biotech Potentially Undervalued Companies

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

4 new

Companies with a Value score of at least 3, ordered by Value score

43 companies

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
MDC Medlab Clinical	AU$6.60	0%	-43.6%	AU$15.1m	n/a	PS9.8x	E-44.7%	n/a
VFY New Vitrafy Life Sciences	AU$1.45	-3.7%	n/a	AU$92.3m	AU$2.32	PB2.7x	E71.3%	n/a
BOT Botanix Pharmaceuticals	AU$0.49	8.9%	151.3%	AU$894.6m	AU$0.65	PS432.3x	E99.4%	n/a
PYC New PYC Therapeutics	AU$1.29	2.8%	61.3%	AU$599.6m	AU$7.67	PS27.2x	E33.5%	n/a
MSB Mesoblast	AU$2.81	-9.9%	869.0%	AU$3.6b	AU$2.70	PS383x	E54.9%	n/a
CTE Cryosite	AU$0.74	0%	9.6%	AU$36.4m	n/a	PE19.8x	n/a	2.7%
TLX Telix Pharmaceuticals	AU$27.00	-6.6%	145.5%	AU$9.1b	AU$25.68	PE185.5x	E30.4%	n/a
IMC Immuron	AU$0.078	1.3%	6.8%	AU$18.0m	AU$0.30	PS3.7x	E22.4%	n/a
CTE Cryosite	AU$0.74	0%	n/a	AU$36.4m	n/a	PE19.8x	n/a	2.7%
MYX Mayne Pharma Group	AU$5.60	19.7%	6.1%	AU$455.0m	AU$6.10	PS1.2x	E111.4%	n/a
BOT Botanix Pharmaceuticals	AU$0.49	8.9%	151.3%	AU$894.6m	AU$0.65	PS432.3x	E99.4%	n/a
MYX Mayne Pharma Group	AU$5.59	18.7%	5.7%	AU$455.0m	AU$6.09	PS1.2x	E111.4%	n/a
VIT Vitura Health	AU$0.12	45.6%	-54.9%	AU$65.4m	n/a	PE18.6x	n/a	0%
VFY New Vitrafy Life Sciences	AU$1.50	-0.3%	n/a	AU$92.3m	AU$2.40	PB2.7x	E71.3%	n/a
IMC Immuron	AU$0.077	2.7%	4.1%	AU$18.0m	AU$0.29	PS3.7x	E22.4%	n/a
PYC New PYC Therapeutics	AU$1.29	2.4%	66.9%	AU$599.6m	AU$7.64	PS27.2x	E33.5%	n/a
VIT Vitura Health	AU$0.11	52.0%	-55.9%	AU$65.4m	n/a	PE18.6x	n/a	0%
TLX Telix Pharmaceuticals	AU$27.08	-6.5%	146.0%	AU$9.1b	AU$25.76	PE185.5x	E30.4%	n/a
MSB Mesoblast	AU$2.80	-10.5%	882.5%	AU$3.6b	AU$2.69	PS383x	E54.9%	n/a

Page 2 of 2